Simplified Access to Medicinal Cannabis in NSW
Simplified Access to Medicinal Cannabis in NSW
Perth, Mar 2, 2018 AEST (ABN Newswire) - MMJ PhytoTech Limited (ASX:MMJ) ("MMJ") welcomes today's announcement by the NSW Government outlining plans to simplify access to medicinal cannabis for doctors and patients in NSW. A copy of that announcement is available at:

http://www.abnnewswire.net/lnk/I15N96IO

The streamlined approval process will see NSW Health partner with the Commonwealth to require a single clinical assessment by the Therapeutic Goods Administration. This key change will eliminate duplication from the current approval process and substantially shorten the time between application and approval for doctors in NSW to prescribe medicinal cannabis to their patients.

This is an important proposed change given that MMJ's largest investment, Harvest One Cannabis Inc. (CVE:HVST), currently supplies Satipharm CBD capsules to approved patients in Australia.


About MMJ PhytoTech Ltd

Phytotech Medical ASX:PYL

In October 2017, MMJ PhytoTech Limited (ASX:MMJ) announced its strategy to become an incubator for strategic investments across regulated jurisdictions globally covering the entire cannabis value chain.

Following the successful listing of United Greeneries Holdings Ltd ("United Greeneries") and Satipharm AG ("Satipharm") on the TSX-V through Harvest One Cannabis Inc. (CVE:HVT), MMJ has focused on the identification of a number of independent strategic investment opportunities that have the potential to deliver significant value to the Company's shareholders.

MMJ is actively pursuing early stage opportunities with the ability to deliver significant future revenue and the opportunity to provide dramatic global synergistic value as regulatory frameworks in key international markets continue to evolve. MMJ is targeting the full range of emerging cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D, hemp food products and retail.

MMJ currently holds an equity stake of 53,333,333 shares in Harvest One, 100% ownership of Israeli-based R&D division PhytoTech Therapeutics Limited ("PTL") and strategic holdings in e-Sense Lab Limited (ASX:ESE) and private Canadian-based company WeedMe Inc.

      


Contact

Investor Enquiries:
Jason Conroy
Chief Executive Officer
E: info@mmjphytotech.com.au

Media Enquiries:
Sam Burns
Six Degrees Investor Relations
M: +61-400-164-067



Related Companies

MMJ PhytoTech Ltd   
Harvest One Cannabis Inc

ABN Newswire This Page Viewed:  (Last 7 Days: 130) (Last 30 Days: 764) (Since Published: 2649) 
ANALYTICS: LOGIN HERE

MMJ PhytoTech Ltd NEWS: RECENT VISITS (22888)

Research Report

Social Media